Limitless Potential.
Precision Design.
Enduring Impact.

Aiming to transform cancer care by developing curative allogeneic cell therapies
PRESS RELEASES + EVENTS view all
10-January-2022
Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies
– Collaboration brings together Century’s industry leading iPSC-derived allogeneic cell therapy platform with Bristol Myers…
04-January-2022
Century Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
PHILADELPHIA, Jan. 04, 2022 (GLOBE NEWSWIRE) — Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company…

About us

We are building a fully integrated biotechnology company that is developing transformational next generation iPSC-derived iNK and iT cell therapies for hematological and solid tumor malignancies.

OUR SCIENCE

We are leveraging the unlimited self-renewing capacity of induced pluripotent stem cells (iPSC) and cutting-edge cellular engineering and manufacturing technologies to develop fit-for-purpose products with functionalities designed to overcome the limitations of existing cell therapies.

Contact us

For business development, media, and all other inquiries.